Paper Details

  1. Home
  2. Paper Details

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.

Author: BissonnetteMarc B, CohenEzra E W, FlemingGini F, GajewskiThomas F, JanischLinda, KarrisonTheodore, MaitlandMichael, PintoNavin, PoliteBlase N, RatainMark J, SalgiaRavi, SehdevAmikar, SharmaManish R, TurcichMichelle, ZhaYuanyuan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Adding metformin to sirolimus did not significantly improve mammalian target of rapamycin (mTOR) inhibition.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor. Metformin may potentiate mTOR inhibition by sirolimus while mitigating its adverse effects. We conducted a pilot study to test this hypothesis. METHODS: Patients with advanced solid tumor were treated with sirolimus for 7 da...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/29948021

データ提供：米国国立医学図書館（NLM）

A Pharmacodynamic Study of Sirolimus and Metformin in Patients with Advanced Solid Tumors

This study investigates the potential benefits of combining sirolimus, an mTOR inhibitor, with metformin, a common diabetes medication, in treating patients with advanced solid tumors. The research employs a [research methodology] approach to assess the pharmacodynamic effects of this combination therapy. The authors have examined the [key findings] related to the impact of metformin on sirolimus's efficacy in inhibiting mTOR, providing valuable insights into the potential synergistic or additive effects of this combination.

Understanding the Potential of Combination Therapy in Cancer Treatment

This research provides a valuable contribution to the field of cancer treatment by exploring the potential of combination therapy. The authors have found that [key findings] regarding the effects of combining sirolimus and metformin on mTOR inhibition. These findings are significant as they help guide future research efforts in this area, potentially leading to more effective treatment strategies for patients with advanced solid tumors.

The Importance of Continued Research in Cancer Treatment

This study highlights the importance of continued research into new and innovative treatments for cancer. While the current findings suggest that metformin may not significantly enhance sirolimus's efficacy, it emphasizes the need for further investigation into the potential of combination therapies in cancer treatment. By exploring the complexities of drug interactions and their impact on tumor response, researchers can continue to develop more effective and personalized treatment approaches for patients battling this disease.

Dr.Camel's Conclusion

This study delves into the world of cancer treatment, highlighting the complexities of drug interactions and their potential impact on patient outcomes. While the findings may not have yielded groundbreaking results in this specific combination, it is a valuable reminder that research is a constant journey of exploration and discovery. This study serves as a stepping stone for further research into the potential of combination therapies in cancer treatment, ultimately aiming to improve the lives of patients battling this complex disease.
Date :
  1. Date Completed 2019-08-01
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

29948021

DOI: Digital Object Identifier

NIHMS1048272

Related Literature

Article Analysis
・Effects of sirolimus
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.